Live Breaking News & Updates on Riikka Viitanen

Stay updated with breaking news from Riikka viitanen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Promising Results from First-in-humans Study of a Novel PET Radiopharmaceutical

Promising Results from First-in-humans Study of a Novel PET Radiopharmaceutical
itnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnonline.com Daily Mail and Mail on Sunday newspapers.

Sirpa Jalkanen , Olli Moisio , Anne Roivainen , Riikka Viitanen , Akademi University , University Of Turku , Turku University Hospital , Researchers Riikka Viitanen , Professor Anne Roivainen , Professor Sirpa , பல்கலைக்கழகம் ஆஃப் டர்கு , டர்கு பல்கலைக்கழகம் மருத்துவமனை ,

Novel PET radiopharmaceutical shows promising results in first-in-humans study

Novel PET radiopharmaceutical shows promising results in first-in-humans study
The preliminary trial results of a novel radiopharmaceutical for PET imaging of inflammation developed at the University of Turku, Finland, have been published. The compound, which targets the vascular adhesion protein 1 (VAP-1) that regulates inflammatory cell traffic, is the first radiopharmaceutical that has been developed completely in Finland and has advanced to clinical trials. In the study that started with healthy volunteers, the radiopharmaceutical was found to be well tolerated and safe.
The radiopharmaceutical is 68Ga-labelled Siglec-9 peptide.
The dose of the radiopharmaceutical used in PET imaging is thousands of times lower when compared with the regular drugs. Studies with new radiopharmaceuticals are therefore safer than the usual drug research studies. ....

Sirpa Jalkanen , Olli Moisio , Riikka Viitanen , Anne Roivainen , Emily Henderson , Akademi University , University Of Turku , Turku University Hospital , Professor Anne Roivainen , Rheumatoid Arthritis , எமிலி ஹென்டர்சன் , பல்கலைக்கழகம் ஆஃப் டர்கு , டர்கு பல்கலைக்கழகம் மருத்துவமனை ,

Promising results from first-in-humans study of a novel PET radiopharmaceutical

E-Mail
IMAGE: The inflamed joints of a rheumatoid arthritis patient are clearly visible in the PET images with the novel 68Ga-DOTA-Siglec-9 radiopharmaceutical.
view more
Credit: Anne Roivainen
The preliminary trial results of a novel radiopharmaceutical for PET imaging of inflammation developed at the University of Turku, Finland, have been published. The compound, which targets the vascular adhesion protein 1 (VAP-1) that regulates inflammatory cell traffic, is the first radiopharmaceutical that has been developed completely in Finland and has advanced to clinical trials. In the study that started with healthy volunteers, the radiopharmaceutical was found to be well tolerated and safe.
The radiopharmaceutical is 68Ga-labelled Siglec-9 peptide. ....

Southwest Finland , Sirpa Jalkanen , Olli Moisio , Riikka Viitanen , Anne Roivainen , Akademi University , Finnish Foundation For Cardiovascular Research , University Of Turku , Academy Of Finland , Finnish Cultural Foundation , Turku University Hospital , Aatos Erkko Foundation , Researchers Riikka Viitanen , Professor Anne Roivainen , Hospital District , Sigrid Jus , Business Finland , Finnish Foundation , Nuclear Medicine , Medicine Health , Clinical Trials , தென்மேற்கு பின்லாந்து , பின்னிஷ் அடித்தளம் க்கு இருதய ஆராய்ச்சி , பல்கலைக்கழகம் ஆஃப் டர்கு , கலைக்கழகம் ஆஃப் பின்லாந்து , பின்னிஷ் கலாச்சார அடித்தளம் ,